Form 4: Acadia Pharmaceuticals CFO Sells Shares
Insider Transaction (Form 4)
Mark C. Schneyer, EVP, CHIEF FINANCIAL OFFICER of Acadia Pharmaceuticals Inc, sold 20,141 shares of common stock on August 5, 2026.
Summary
- Option exercise/conversion: acquired 5,849 Common Stock at $17.84 ($104,346) on August 5, 2026; holds 73,677 after (Direct).
- Open-market sale: disposed of 5,849 Common Stock at $29.00 ($169,638) on August 5, 2026; holds 67,828 after (Direct).
- Option exercise/conversion: acquired 14,292 Common Stock at $17.84 ($254,969) on August 6, 2026; holds 82,120 after (Direct).
- Open-market sale: disposed of 5,000 Common Stock at $29.00 ($145,000) on August 6, 2026; holds 77,120 after (Direct).
- Open-market sale: disposed of 9,292 Common Stock at $29.34 ($272,604) on August 6, 2026; holds 67,828 after (Direct).
- Option exercise/conversion: disposed of 5,849 Stock Option (Right to Buy) on August 5, 2026; holds 74,715 after (Direct).
- Option exercise/conversion: disposed of 14,292 Stock Option (Right to Buy) on August 6, 2026; holds 60,423 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $587,242 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Mark C. Schneyer — Officer (EVP, CHIEF FINANCIAL OFFICER)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-05 | Option exercise/conversion | Common Stock | 5,849 | $18 | $104.3K | 73,677 |
| 2026-08-05 | Open-market sale | Common Stock | 5,849 | $29 | $169.6K | 67,828 |
| 2026-08-06 | Option exercise/conversion | Common Stock | 14,292 | $18 | $255.0K | 82,120 |
| 2026-08-06 | Open-market sale | Common Stock | 5,000 | $29 | $145.0K | 77,120 |
| 2026-08-06 | Open-market sale | Common Stock | 9,292 | $29 | $272.6K | 67,828 |
| 2026-08-05 | Option exercise/conversion | Stock Option (Right to Buy) | 5,849 | — | — | 74,715 |
| 2026-08-06 | Option exercise/conversion | Stock Option (Right to Buy) | 14,292 | — | — | 60,423 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-05 | Option exercise/conversion (5,849 shares) |
| 2026-08-05 | Open-market sale (5,849 shares) |
| 2026-08-06 | Option exercise/conversion (14,292 shares) |
| 2026-08-06 | Open-market sale (5,000 shares) |
| 2026-08-06 | Open-market sale (9,292 shares) |
| 2026-08-05 | Option exercise/conversion (5,849 shares) |
| 2026-08-06 | Option exercise/conversion (14,292 shares) |
Keywords
insider transaction, Form 4, ACAD, ACADIA PHARMACEUTICALS INC, bearish, Mark C. Schneyer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.